
A look back on a conference to shape LAMA2 clinical care guidelines
We are delighted to reflect on the success of the ENMC conference, initiated by Voor Sara and Cure CMD. Together,…
Our mission is to further advance awareness and research for LAMA2-CMD internationally and to directly support patients and families by providing relevant information and resources.
This website brings together the international LAMA2-CMD community and centralises all information, education, community news and research and industry updates directly relating to the fight against LAMA2-CMD.
By including the patients and families, and by collaborating with the clinicians, researchers and members of the biotech industry involved with LAMA2-CMD around the world, we aim to accelerate the road to therapy in a truly united and collective global effort.
Find more on our objectives and who we are here.
We are delighted to reflect on the success of the ENMC conference, initiated by Voor Sara and Cure CMD. Together,…
In september 2023 we started the LAMA2-CMD consortium meetings for researchers, clinicians, companies and patients and their representatives. These meetings…
In January 2025, clinicians specialising in LAMA2-Congenital Muscular Dystrophy (LAMA2-CMD) will convene in The Netherlands to begin developing updated care…
Modalis Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to…
In 2022, a natural history study was initiated with LAMA2-CMD patients at Barcelona’s Vall d’Hebron Institute of Research. Natural history…
We are thrilled to announce a new clinical workshop focused on establishing subtype-specific care recommendations for LAMA2-RD, and using this experience as a prototype to develop recommendations for…
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
Dr Reghan Foley has recently started a new research project in collaboration with the University College Cork / Cork’s University…
Dr. Dwi Kemaladewi and her team at the University of Pittsburgh have been diligently working on the development of a…
Meet 25-year-old Mo and 16-year-old Hidde from The Netherlands, both living with LAMA2-CMD. In this short documentary produced by the…
Professor Dr Madeleine Durbeej of Lund University, Sweden provided an overview of existing research on the mechanisms of LAMA2-CMD and…
On the 17-19th of March 2023 doctors, researchers, patients and families gathered in Barcelona for the second international conference on…
This month, Maastricht UMC, led by Professor Bert Smeets, started a first clinical study in which healthy stem cells from…
Hello everyone, From 17 till 19 March there will be an international conference about Lama2-MD in Barcelona. The conference LAMA2…
Muscles On Wheels: a children’s book about a girl in a wheelchair! This special story is written by three students…
Meet Justin: an exceptional young man who, despite living with the LAMA2-CMD, has been living his life to the fullest…
Dr. Avencia Sanchez-Mejías has been investigating how haematopoietic stem cells from LAMA2-CMD patients’ bone marrow, can be genetically corrected to…
Patient Organisation
Founded by the parents of Marko in 2023, LAMA2 Bulgaria aims to accelerate the path to clinical trials by connecting affected families in Bulgaria.
Find more information here.
Who: Dr. Francina Munell and Dr. Jordi Barquinero
Where: Barcelona, Spain
Research: Diagnostics and stem cell therapy for LAMA2-CMD patients
Do you have a question for one of the experts or researchers with whom we are in contact? About an investigation, a treatment method or other information that you are looking for? Submit your question and we will get you a personal answer as soon as possible. We will also publish the answer on this website.